bimekizumab
ucb pharmaceuticals
['bimekizumab']
congress #acr22 | discussed week 16 results from a phase iii study of bimekizumab in pts with active #psoriaticarthritis and inadequate response to tnf inhibitors. all primary and secondary endpoints were met at week 16, with no new safety signals observed. 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.